3rd Medical Oncology Department

The Clinic
Recent Publications

The 3rd Department of Medical Oncology is staffed by specialized physicians who provide comprehensive care and support to the oncology patient. Our team consists of 3 Oncologists who have studied abroad and have extensive clinical experience, in addition to two Internists. This primary team is also assisted by one junior doctor, three nurses, and administrative staff who contribute to the care of our patients.

Historically, our group was founded by Dr. Dennis V. Razis and became the first private Oncology Department in Greece. The group was taken over in the last few years by his daughter, Dr. Evangelia Razis, who continues the founder’s pioneering activity until today.

The aim of our group is to offer modern diagnostic and therapeutic medical services, and continuous comprehensive support for oncology patients and their families.

Our doctors dedicate much of their time to remaining current with the latest trends and are actively involved in various research programs and clinical studies, thus giving our patients access to innovative treatments. They also have an active presence at many conferences and publications in international high impact factor journals. Additionally, our doctors collaborate with prominent international centers and can arrange a mail review of a patient’s record when necessary.

C.Liakou, J.Koh, A.Tsimpidakis, K.Rios, H.Paskalis, A.Pipilis, T.Georgiadis, E.Razis. A tongue lesion as a sign of a systemic disease. Case Rep Med. 2016;2016:6723575. Epub 2016 Mar 22.
S.Lakis, S.Dimoudis, V.Kotoula, Z.Alexopoulou, I.Kostopoulos, T.Koletsa, M.Bobos, E.Timotheadou, I.Papaspirou, I.Efstratiou, G.Aravantinos, V.Karavasilis, F.Zagouri, H.Gogas, E.Razis, G.Pentheroudakis, C.Christodoulou, D.Pectasides, G.Fountzilas. Interaction between beta-catenin and EGFR expression by immunohistochemistry identifies prognostic subgroups in early high-risk triple negative breast cancer. Anticancer Res. 2016 May;36(5):2365-78.
G.Rigakos, A.Vakos, S.Papadopoulos, A.Vernadou, A.Tsimpidakis, D. Papachristou, E.Razis. Cancer of unknown primary ultimately diagnosed as male breast cancer: A rare case report. Mol Clin Oncol. 2016 Aug;5(2):263-266. Epub 2016 May 24.
P.Apostolou, M.Pertesi, V.Aleporou-Marinou, C.Dimitrakakis, C.Papadimitriou, E.Razis, C.Christodoulou, G.Fountzilas, D.Yannoukakos, I.Konstantopoulou, F.Fostira. Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation Clin Genet. 2017 Mar;91(3):482-487. Epub 2016 Aug 22.
V.Kotoula; S.Lakis; I.Vlachos; E.Giannoulatou; F.Zagouri; Z.Alexopoulou; H.Gogas; D.Pectasides; G.Aravantinos; I.Efstratiou; G.Pentheroudakis; K.Papadopoulou; K.Chatzopoulos; P.Papakostas; M.Sotiropoulou; I.Nicolaou; E.Razis; A.Psyrri; P.Kosmidis; C.Papadimitriou; G.Fountzilas; Tumor infiltrating lymphocytes affect the outcome of patients with operable triple-negative breast cancer in combination with mutated amino acid classes. PLoS One. 2016 Sep 29;11(9):e0163138.
S.Ndarukwa, A.M.Nyakabau, A.B.Chagpar, D.Raben, N.Ndlovu, W.Kadzatsa, V.J.Eaton, P.Mafunda, E.Razis. American Society of Clinical Oncology Multidisciplinary Cancer Management Course: Connecting Lives, Cancer Care, Education, and Compassion in Zimbabwe—A Pilot for Efforts of Sustainable Benefit? JGO.2016.003673.
E.Razis. QOPI International… or How to globalize quality? JGO.2016.006437.
E.Fountzilas, V.Kotoula, F.Zagouri, E.Giannoulatou, G.Kouvatseas, G.Pentheroudakis, T.Koletsa, M.Bobos, K.Papadopoulou, E.Samantas, E.Demiri, S.Miliaras, C.Christodoulou, S.Chrisafi, E.Razis, F.Fostira, D.Pectasides, G.Zografos, G.Fountzilas. Disease evolution and heterogeneity in bilateral breast cancer. Am J Cancer Res. 2016 Nov 1;6(11):2611-2630. eCollection 2016.
G.Rigakos, C.Liakou, N.Felipe, D.Orkoulas-Razis, E.Razis. Neoplastic meningitis: clinical presentation, differential diagnosis, radiology, diagnosis. Cancer Control. Jan 2017, Vol. 24, No.1.
V.Kotoula, F.Fostira, K.Papadopoulou, P.Apostolou, E.Tsolaki, G.Lazaridis, K.Manoussou, F.Zagouri, D.Pectasides, I.Vlachos, I.Tikas, S.Lakis, I.Konstantopoulou G.Pentheroudakis, H.Gogas, P.Papakostas, C.Christodoulou, D.Bafaloukos; E.Razis, V.Karavasilis, C.Bamias, D.Yannoukakos, G.Fountzilas. The fate of BRCA1-related germline mutations in triple-negative breast tumors. Am J Cancer Res. 2017; 7(1): 98–114.
T.Strati, V.Kotoula, I.Kostopoulos, K.Manousou, C.Papadimitriou, G.Lazaridis, S.Lakis, G.Pentheroudakis, D.Pectasides, E.Pazarli, C.Christodoulou, E.Razis, K.Pavlakis, C.Magkou, S.Chrisafi, G.Aravantinos, D.Bafaloukos, P.Papakostas, H.Gogas, K.T.Kalogeras, G.Fountzilas. Prognostic subcellular Notch2, Notch3 and Jagged1 localization patterns in early triple-negative breast cancer. Anticancer Res. 2017 May; 37(5):2323-2334.
A.Batistatou, V.Kotoula, M.Bobos, G.Kouvatseas, F.Zagouri, E.Tsolaki, H.Gogas, A.Koutras, G.Pentheroudakis, E.Timotheadou, S.Pervana, A.Goussia, K.Petraki, M.Sotiropoulou, T.Koletsa, E.Razis, P.Kosmidis, G.Aravantinos, C.Papadimitriou, D.Pectasides, G.Fountzilas. Correlation of MYC gene and protein status with breast cancer subtypes and outcome of patients treated with anthracycline-based adjuvant chemotherapy. Pooled analysis of two Hellenic Cooperative Group phase III trials. Clin Breast Cancer. 2017 Jul 13. pii: S1526-8209(17)30138-6. doi: 10.1016/j.clbc.2017.07.004.
S.Levva, V.Kotoula, I.Kostopoulos, K.Manousou, C.Papadimitriou, K.Papadopoulou, S.Lakis, KKoukoulias, V.Karavasilis, G.Pentheroudakis, E.Balassi, Z.Flora, I.G.Kaklamanos, D.Pectasides, E.Razis, G.Aravantinos, P.Papakostas, D.Bafaloukos, R.Grigorios, H.Gogas, G.Fountzilas. Prognostic evaluation of epidermal growth factor receptor (EGFR) genotype and phenotype parameters in triple-negative breast cancers. Cancer Genomics Proteomics. 2017 May-Jun; 14(3):181-195.
G.Rigakos, A.Kyriazoglou, A.Vernadou, S.Papadopoulos, E.Skarpidi, P.Nomikos, C.Dardoufas, G.Nassioulas, G.Kouvatseas, O.Spyri, S.Labropoulos, E.Razis. Bevacizumab in high grade glioma: Is there a subgroup that benefits? (2017) Hematol Med Oncol, Volume 2(4): 1-7.
C.Christodoulou, A.Kalogera-Fountzila, V.Karavasilis, G.Kouvatseas, CN.Papandreou, E.Samantas, K.Varaki, G.Papadopoulos, M.Bobos, G.Rallis, E.Razis, A.Goudopoulou, KT.Kalogeras, KN.Syrigos, G.Fountzilas. Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG). J Neurooncol. 2017 Sep;134(2):443-451. doi: 10.1007/s11060-017-2548-z.
M.Georgakis, P.Panagopoulou, P.Papathoma, A.Tragiannidis, A.Ryzhov, S.Zivkovic-Perisic, S.Eser, L.Taraszkiewicz, M.Sekerija, T.Zagar, L.Antunes, A.Zborovskaya, J.Bastos, M.Florea, D.Coza, A.Demetriou, D.Agius, R.M Strahinja., G.Sfakianos, I.Nikas, S.Kosmidis, E.Razis, A.Pourtsidis, M.Kantzanou, N.Dessypris, E.Th.Petridou. Central nervous system tumours among adolescents and young adults (15-39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US. European Journal of Cancer 86 (2017) 46e58.